Vault-13

Abingworth LLP

LONDON, X0 · CIK 1397144 · 13F filing filed 2022-08-15

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

Other 13F filers in this group: Carlyle Group Inc. $10.0bn, AlpInvest Partners B.V. $59.9m, Carlyle Investment Management LLC files a notice

As an employer

In the UK

CompanyTownStaffPay gap reportFCA register
ABINGWORTH LLP Limited Liability PartnershipFCA: Authorised · manages AIFs London Authorisedmanages AIFs
CELF ADVISORS LLP Limited Liability PartnershipFCA: Authorised · manages investments, advises, deals London Authorisedmanages investments, advises, deals

Sources: Companies House (accounts filed electronically; the largest groups often file on paper, so their staff numbers can be missing), the UK gender pay gap service (employers with 250+ staff) and the FCA's Financial Services Register. Contains public sector information licensed under the Open Government Licence v3.0.

$312.4m reported value -11.4% vs Q1 2022
21positions
95.7%in top 10
1 new 2 added 2 reduced 0 sold out vs Q1 2022

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 VAXCYTE INC COM PCVX PCVX 4,168,718 $90.7m29.04% 29.04% UnchangedShares held: Q3 2021 4.2m, Q4 2021 4.2m, Q1 2022 4.2m, Q2 2022 4.2m
2 SIERRA ONCOLOGY INC COM SRRA SRRA 1,314,127 $72.3m23.14% 23.14% AddedShares held: Q3 2021 876.7k, Q4 2021 876.7k, Q1 2022 1.3m, Q2 2022 1.3m +115 +115 0.0%
3 VERA THERAPEUTICS INC CL A VERA VERA 2,960,231 $40.3m12.90% 12.90% UnchangedShares held: Q3 2021 3.0m, Q4 2021 3.0m, Q1 2022 3.0m, Q2 2022 3.0m
4 ADICET BIO INC COM COM 2,115,385 $30.9m9.89% 9.89% UnchangedShares held: Q3 2021 1.6m, Q4 2021 2.1m, Q1 2022 2.1m, Q2 2022 2.1m
5 HILLEVAX INC COM COM 1,838,486 $19.9m6.38% 6.38% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 1.8m
6 PHATHOM PHARMACEUTICALS INC COM PHAT PHAT 1,435,106 $12.1m3.88% 3.88% UnchangedShares held: Q3 2021 1.2m, Q4 2021 1.2m, Q1 2022 1.4m, Q2 2022 1.4m
7 JASPER THERAPEUTICS INC COM COM 5,628,558 $10.6m3.41% 3.41% UnchangedShares held: Q3 2021 5.6m, Q4 2021 5.6m, Q1 2022 5.6m, Q2 2022 5.6m
8 VERONA PHARMA PLC SPONSORED ADS VRNA VRNA 2,457,500 $10.2m3.26% 3.26% AddedShares held: Q3 2021 2.5m, Q4 2021 2.5m, Q1 2022 2.5m, Q2 2022 2.5m +1 +1 0.0%
9 EFFECTOR THERAPEUTICS INC COM COM 4,822,114 $6.5m2.07% 2.07% UnchangedShares held: Q3 2021 4.8m, Q4 2021 4.8m, Q1 2022 4.8m, Q2 2022 4.8m
10 RENEO PHARMACEUTICALS INC COM COM 2,073,957 $5.4m1.73% 1.73% UnchangedShares held: Q3 2021 2.1m, Q4 2021 2.1m, Q1 2022 2.1m, Q2 2022 2.1m
11 SOLENO THERAPEUTICS INC COM NEW SLNO SLNO 18,022,602 $3.2m1.01% 1.01% UnchangedShares held: Q3 2021 10.3m, Q4 2021 10.3m, Q1 2022 18.0m, Q2 2022 18.0m
12 Spruce Bio COMMON COMMON 1,792,518 $3.1m0.99% 0.99% UnchangedShares held: Q3 2021 1.8m, Q4 2021 1.8m, Q1 2022 1.8m, Q2 2022 1.8m
13 NUCANA PLC SPONSORED ADR SPONSORED ADR 3,333,333 $2.4m0.77% 0.77% UnchangedShares held: Q3 2021 3.3m, Q4 2021 3.3m, Q1 2022 3.3m, Q2 2022 3.3m
14 PARATEK PHARMACEUTICALS INC COM PRTK PRTK 1,041,131 $2.0m0.64% 0.64% UnchangedShares held: Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 1.0m, Q2 2022 1.0m
15 SIENTRA INC COM SIEN SIEN 1,673,589 $1.4m0.44% 0.44% ReducedShares held: Q3 2021 2.3m, Q4 2021 2.3m, Q1 2022 2.3m, Q2 2022 1.7m -676.2k -676,238 -28.8%
16 EXICURE INC COM XCUR XCUR 281,636 $594.0k0.19% 0.19% ReducedShares held: Q3 2021 7.0m, Q4 2021 7.0m, Q1 2022 7.0m, Q2 2022 281.6k -6.7m -6,695,364 -96.0%
17 CYMABAY THERAPEUTICS INC COM CBAY CBAY 131,036 $385.0k0.12% 0.12% UnchangedShares held: Q3 2021 131.0k, Q4 2021 131.0k, Q1 2022 131.0k, Q2 2022 131.0k
18 MOLECULAR TEMPLATES INC COM COM 200,000 $182.0k0.06% 0.06% UnchangedShares held: Q3 2021 200.0k, Q4 2021 200.0k, Q1 2022 200.0k, Q2 2022 200.0k
19 OBSEVA SA COM COM 87,999 $141.0k0.05% 0.05% UnchangedShares held: Q3 2021 88.0k, Q4 2021 88.0k, Q1 2022 88.0k, Q2 2022 88.0k
20 AEGLEA BIOTHERAPEUTICS INC COM AGLE AGLE 240,500 $121.0k0.04% 0.04% UnchangedShares held: Q3 2021 240.5k, Q4 2021 240.5k, Q1 2022 240.5k, Q2 2022 240.5k
21 HISTOGENICS CORP COM COM 7,111 $16.0k0.01% 0.01% UnchangedShares held: Q3 2021 7.1k, Q4 2021 7.1k, Q1 2022 7.1k, Q2 2022 7.1k